查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球胃食管反流药物市场-2022-2029
市场调查报告书
商品编码
1140695

全球胃食管反流药物市场-2022-2029

Global Gastroesophageal Reflux Disease Therapeutics Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 160 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概览

在预测期间（2022-2029 年），胃食管反流药物的市场规模预计将以 4% 的复合年增长率增长。

GERD 是由胃内容物（包括酸、食物和液体）回流到食道引起的消化系统疾病。它会刺激食道黏膜，使患者有灼烧感。胃灼热（反流）和反流是 GERD 最常见的两种食管症状。在大多数情况下，饮食和生活方式的改变可以缓解 GERD 症状。但是，有些人可能需要药物或手术。

市场动态

胃食管反流病的最新疗法有望推动市场增长。

TIF（经口无切口资助）是治疗 GERD 的手术之一。与腹腔镜手术相比，TIF具有治疗週期短、疼痛小、恢復快的特点。 TIF 用于为内窥镜（一种柔性管状成像设备）创建通道。这种治疗使用预设的镊子和紧固件来修復或更换阀门，作为防止回流的天然屏障。目前正在进行临床试验，以确认内镜治疗 GERD 的疗效。使用内窥镜缝纫机将缝线插入胃中以增加抗反流屏障。因此，上述声明预计将在预测期内推动市场。

约束

与药物相关的副作用预计会阻碍市场增长。

COVID-19 影响分析

COVID-19 大流行对医疗保健系统和市场产生了适度影响。巴雷特食管 (BE) 和胃食管反流病 (GERD) 是与 COVID-19 相关的潜在新兴合併症。 BE 是一种 GERD 破坏食管鳞状上皮的疾病，据说在美国影响 5.6% 的人。 ACE2在BE患者食管中明显表达，表明与本病相关的酸性pH是促进ACE2表达的重要因素。已发现感染 SARS-CoV-2 的人类原代单核细胞在较低 pH 值下培养时表达更多 ACE2 并具有更高的病毒载量。

此外，还发现服用通常用于治疗 GERD 的质子泵抑製剂的人更有可能患上严重的 COVID-19，如 ICU 入院率和死亡率增加所示。此外，大流行将扰乱供应链。许多公司转移到其他地区以确保产品可用性并保护其供应链。这样，市场受到影响，但随着经济活动的恢復，预计会迅速蔓延。

此外，服用通常用于治疗 GERD 的质子泵抑製剂的人也更有可能患上严重的 COVID-19，如 ICU 入院和死亡率增加所见。事实证明。此外，大流行将扰乱供应链。许多公司转移到其他地区以确保产品可用性并保护其供应链。综上所述，市场受到了影响，但随着经济活动的恢復，预计将迅速领先。

细分分析

质子泵抑製剂部分有望在胃食管反流药物市场占有最大的市场份额

预计 2021 年将由质子泵抑製剂市场主导。质子泵抑製剂 (PPI) 是最广泛使用的胃灼热药物。它是用于停止酸生产的最强选项，并且是常用的，因此非常方便。此外，据报导，它可以有效预防反流症状和食管糜烂/溃疡的复发。例如，埃索美拉唑 (Nexium) 用于治疗成人和一岁以上儿童的胃食管反流病 (GERD)，其中胃酸反流会导致胃灼热和食道（喉咙和胃之间的管道）受损。它是一种处方药，用作因此，对胃食管反流病的治疗剂的需求不断增加。因此，从以上描述来看，这种市场细分预计将在预测期内占据最大的市场份额。

区域分析

北美在全球胃食管反流药物市场占有最大的市场份额

北美在 2021 年的收入份额最高。老年人口的增加、肥胖病例的增加、完善的基础设施、胃食管反流药物的使用增加、该地区临床试验数量的增加等是预计在预测期内推动市场发展的因素。例如，根据美国疾病控制和预防中心的数据，美国每个州和地区的肥胖率都在 20% 以上。总体而言，女性的成人肥胖率较高。此外，肥胖儿童的比例正在增加，据说到2020年将有3900万五岁以下儿童超重或肥胖。此外，与肥胖相关的医疗保健每年花费美国约 1500 亿美元，四分之一的年轻人超重而无法加入美国军队。

此外，Ironwood Pharmaceuticals, Inc. 于 2021 年进行了一项临床试验，以评估将 IW-3718 用于 GERD 患者的安全性和有效性。因此，对胃食管反流病药物的需求正在增加。因此，从上述陈述来看，预计北美地区将在预测期内占据最大的市场份额。

竞争格局

概述

AstraZeneca Plc 是一家发现、生产和商业化各种处方药的生物製药公司。我们专注于治疗领域，如呼吸、心血管、肾臟、代谢、癌症、自身免疫、传染病和神经系统疾病。该公司的产品组合包括生物製剂、处方药和疫苗。阿斯利康通过全资拥有的当地销售公司、分销商和当地代表处销售其产品。该公司将其产品销售给初级和专科保健医生。在 100 多个国家开展业务，其创新药物被全球数百万患者使用。

产品组合

Nexium（埃索美拉唑镁）：一种质子泵抑製剂，适用于治疗胃食管反流病 (GERD) 和使用 NSAID 降低胃溃疡风险。

全球胃食管反流药物市场报告提供对大约 45 多个市场数据表、40 多个数字和 160 页的访问。

内容

第1章研究方法与范围

  • 调查方法
  • 调查目的和范围

第 2 章市场定义和概述

第 3 章执行摘要

  • 按类型划分的市场细分
  • 按药物类别划分的市场细分
  • 按分销渠道划分的市场细分
  • 按地区划分的市场细分

第 4 章市场动态

  • 市场影响因素
    • 驱动程序
      • 胃食管反流病的现代疗法有望推动市场增长。
    • 限制
      • 与药物相关的副作用预计会阻碍市场增长
    • 机会
    • 影响分析

第5章行业分析

  • 供应链分析
  • 定价分析
  • 未满足的需求分析

第 6 章 COVID-19 分析

  • COVID-19 的市场分析
    • COVID-19 之前的市场情景
    • COVID-19 的当前市场情景
    • COVID-19 后或未来情景
  • COVID-19 期间的价格动态
  • 供需范围
  • 大流行期间与市场相关的政府举措
  • 製造商的战略举措
  • 总结

第 7 章按类型

  • 温和
  • 中等
  • 严重

第 8 章药物类别

  • 抗酸剂
    • 氢氧化铝凝胶（Alternagel、Amphojel）
    • 碳酸钙（Alka-Seltzer、Tums）
    • 氧化镁奶
    • Pepto Bismol
    • 其他
  • 质子泵抑製剂
    • 埃索美拉唑（耐信）
    • 兰索拉唑（前酸）
    • 奥美拉唑（Prilosec，Zegerid）
    • 泮托拉唑（Protonix）
    • 雷贝拉唑（Aciphex）
    • 右兰索拉唑（Dexilant）
    • 其他
  • 组胺阻滞剂
    • 西咪替丁（Tagamet HB）
    • 法莫替丁 (Pepsid AC)
    • 尼扎替丁
    • 其他
  • 促动力剂
  • 其他

第 9 章分销渠道

  • 医院药房
  • 零售药房
  • 在线药店
  • 其他

第 10 章按地区划分

  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 意大利
    • 西班牙
    • 其他欧洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 澳大利亚
    • 其他亚太地区
  • 中东和非洲

第 11 章竞争格局

  • 主要发展和战略
  • 公司份额分析
  • 产品基准
  • 值得关注的重点公司列表

第 12 章公司简介

  • Merck Sharp & Dohme Pty Ltd.
    • 公司概况
    • 产品组合和描述
    • 主要亮点
    • 财务摘要
  • McNeil Consumer Pharmaceuticals Co.
  • Amneal Pharmaceuticals LLC
  • AstraZeneca Pharmaceuticals LP
  • Teva Pharmaceuticals USA, Inc.
  • Takeda Pharmaceuticals America, Inc.
  • Eisai R&D Management Co., Ltd
  • TWi Pharmaceuticals USA, Inc.
  • Lannett
  • Saol Therapeutics Inc（*LIST NOT EXHAUSTIVE）

第13章 DataM

简介目录
Product Code: DMPH5060

Market Overview

Gastroesophageal Reflux Disease Therapeutics Market size was valued US$ XX million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 4 % during the forecast period (2022-2029).

GERD is a digestive disorder that occurs when stomach contents such as acid, food, and fluids reflux into the esophagus. It irritates the esophageal lining, resulting in patients experiencing a burning sensation. Heartburn (reflux) and regurgitation are two of GERD's most common esophageal symptoms. In most cases, GERD symptoms can ease through diet and lifestyle changes. But some people may need medication or surgery.

Market Dynamics

The latest treatment for Gastroesophageal Reflux Disease is expected to drive market growth.

TIF (transoral incisionless fundoplication) is a procedure for treating GERD. Compared to laparoscopic surgery, TIF can result in quicker treatment duration, less pain, and a speedier recovery. A specific TIF device is used to make a path for an endoscope, a flexible, tube-like imaging instrument. The treatment allows the doctor to repair or replace the valve that acts as a natural barrier to reflux using preloaded tweezers and fasteners. Currently, clinical trials are being conducted to determine the efficacy of endoscopic therapy for GERD. An endoscopic sewing machine is used to insert stitches in the stomach, increasing the anti-reflux barrier. Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Side effects associated with the drugs is expected to hamper the market growth.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Barrett's esophagus (BE) and gastroesophageal reflux disease (GERD) may be new comorbidities linked to COVID-19. BE, a disease in which GERD destroys the esophagus squamous mucosa, affects 5.6 percent of individuals in the United States. ACE2 is significantly expressed in the esophagus of BE patients, and the acid pH associated with the disease is a crucial inducer of ACE2 expression. When human primary monocytes are infected with SARS-CoV-2, they express more ACE2 and have a larger viral load when grown at a lower pH.

Moreover, it also discovered that individuals on proton pump inhibitors, commonly prescribed for GERD, have a higher chance of developing severe COVID-19, as seen by increased ICU admission and death rates. Additionally, the pandemic interrupts the supply chain. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Moreover, it also discovered that individuals on proton pump inhibitors, commonly prescribed for GERD, have a higher chance of developing severe COVID-19, as seen by increased ICU admission and death rates. Additionally, the pandemic interrupts the supply chain. Many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Proton Pump Inhibitors segment is expected to hold the largest market share in gastroesophageal reflux disease therapeutics market

The proton pump inhibitors segment is expected to dominate in 2021. Proton pump inhibitors (PPIs) are the most widely used heartburn medication. They are the strongest available option for stopping acid production and are very convenient because they're so commonly used. Moreover, they are reported to effectively prevent the recurrence of reflux symptoms and esophageal erosions/ulcers. For instance, Esomeprazole (Nexium) is the prescription drug used to treat the symptoms of gastroesophageal reflux disease (GERD), a condition in which the backward flow of acid from the stomach causes heartburn and possible injury to the esophagus (the tube between the throat and stomach) in adults and children 1 year of age and older. Therefore, it has increased the demand for drugs to treat gastroesophageal reflux disease. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global gastroesophageal reflux disease therapeutics market

North America accounted for the highest revenue share in 2o21. Rising geriatric population, increasing prevalence of obesity cases, well-established infrastructure, increasing adoption of drugs for the gastroesophageal reflux disease and increasing clinical trials in the region are some factors the market is expected to boost in the forecast period. For instance, according to the Centers for Disease Control and Prevention, All U.S. states and territories have an obesity rate of at least 20%. Overall, adult obesity rates are higher for women. The percentage of obese children is rising, with 39 million overweight and obese children under age five in 2020. Moreover, the U.S. spends almost $150 billion per year on obesity-related medical costs, and early one in four young adults is too heavy to serve in the U.S. military.

Additionally, Ironwood Pharmaceuticals, Inc. conducted clinical trials in 2021 to evaluate the safety and efficacy of IW-3718 administered to patients with GERD. Therefore, it has increased the demand for gastroesophageal reflux drugs. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the gastroesophageal reflux disease therapeutics market Merck Sharp & Dohme Pty Ltd., McNeil Consumer Pharmaceuticals Co., Amneal Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP, Teva Pharmaceuticals USA, Inc., Takeda Pharmaceuticals America, Inc., Eisai R&D Management Co., Ltd, TWi Pharmaceuticals USA, Inc., Lannett and Saol Therapeutics Inc.

AstraZeneca Pharmaceuticals LP:

Overview:

AstraZeneca Plc (AstraZeneca) is a biopharmaceutical company, which discovers, produces and commercializes a wide range of prescription drugs. It focuses on therapy areas such as respiratory, cardiovascular, renal and metabolic diseases; and cancer, besides autoimmune, infection and neurological diseases. The company's product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. It operates in over 100 countries, and its innovative medicines are used by millions of patients worldwide.

Product Portfolio:

NEXIUM (esomeprazole magnesium): It is a proton pump inhibitor indicated for treating gastroesophageal reflux disease (GERD) and risk reduction of NSAID-associated gastric ulcers.

The global gastroesophageal reflux disease therapeutics market report would provide an access to an approx. 45+market data table, 40+figures and 160pages.

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

  • 3.1. Market Snippet by Type
  • 3.2. Market Snippet by Drug Class
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The latest treatment for Gastroesophageal Reflux Disease is expected to drive market growth.
    • 4.1.2. Restraints:
      • 4.1.2.1. Side effects associated with the drugs is expected to hamper the market growth.
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Supply Chain Analysis
  • 5.2. Pricing Analysis
  • 5.3. Unmet Needs

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type Segment
  • 7.2. Mild*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Moderate
  • 7.4. Severe

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class Segment
  • 8.2. Antacids*
    • 8.2.1. Aluminum hydroxide gel (Alternagel, Amphojel)
    • 8.2.2. Calcium carbonate (Alka-Seltzer, Tums)
    • 8.2.3. Magnesium hydroxide (Milk of Magnesia)
    • 8.2.4. Pepto-Bismol
    • 8.2.5. Others
    • 8.2.6. Introduction
    • 8.2.7. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Proton Pump Inhibitors
    • 8.3.1. Esomeprazole (Nexium)
    • 8.3.2. Lansoprazole (Prevacid)
    • 8.3.3. Omeprazole (Prilosec, Zegerid)
    • 8.3.4. Pantoprazole (Protonix)
    • 8.3.5. Rabeprazole (Aciphex)
    • 8.3.6. Dexlansoprazole (Dexilant)
    • 8.3.7. Others
  • 8.4. Histamine blockers
    • 8.4.1. Cimetidine (Tagamet HB)
    • 8.4.2. Famotidine (Pepcid AC)
    • 8.4.3. Nizatidine
    • 8.4.4. Others
  • 8.5. Pro-Kinetic Agents
  • 8.6. Others

9. By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Retail Pharmacy
  • 9.4. Online Pharmacy
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Merck Sharp & Dohme Pty Ltd.*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. McNeil Consumer Pharmaceuticals Co.
  • 12.3. Amneal Pharmaceuticals LLC
  • 12.4. AstraZeneca Pharmaceuticals LP
  • 12.5. Teva Pharmaceuticals USA, Inc.
  • 12.6. Takeda Pharmaceuticals America, Inc.
  • 12.7. Eisai R&D Management Co., Ltd
  • 12.8. TWi Pharmaceuticals USA, Inc.
  • 12.9. Lannett
  • 12.10. Saol Therapeutics Inc(*LIST NOT EXHAUSTIVE)

13. DataM Intelligence

  • 13.1. Appendix
  • 13.2. About Us and Applications
  • 13.3. Contact Us